Form 4: Bausch Health GC Reports RSU Grant, Share Sales

Bausch Health's EVP and General Counsel, Seana Carson, reported an award of restricted share units and subsequent sales of common shares, including tax-related withholdings and an open market sale under a 10b5-1 plan.

Summary

• Seana Carson, Executive Vice President and General Counsel of Bausch Health Companies Inc. (BHC), reported changes in her beneficial ownership of common shares.
• On February 25, 2026, Carson was awarded 212,350 restricted share units (RSUs) at a price of $0.
• These RSUs are scheduled to vest one-third on each of the first three anniversaries following the grant date, subject to Carson's continued service.
• Following the RSU award, Carson's beneficial ownership increased to 849,857 common shares.
• On February 26, 2026, 32,211 common shares were withheld to satisfy tax withholding obligations due upon the vesting of Restricted Share Units, at a price of $6.04 per share, reducing ownership to 817,646 shares.
• On February 27, 2026, Carson sold 8,388 common shares in the open market at a price of $5.95 per share.
• This open market sale was conducted pursuant to a Rule 10b5-1 plan adopted by Carson on May 7, 2025.
• After all reported transactions, Carson's beneficial ownership stands at 809,258 common shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. While an RSU grant is positive for executive alignment, the subsequent sales are routine for tax purposes and pre-planned, not indicating a significant change in company fundamentals or insider sentiment.

Positives

• The award of 212,350 restricted share units (RSUs) to a key executive aligns management incentives with long-term shareholder value.

Negatives

• The open market sale of 8,388 common shares by a key executive, even if pre-planned, represents a reduction in insider holdings.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that insider transactions, such as RSU grants and subsequent share sales for tax purposes or under pre-arranged 10b5-1 plans, are standard practices in executive compensation and personal financial planning across various industries. These transactions typically reflect routine compensation events rather than significant shifts in company outlook or insider sentiment.

Comparison to Industry Standards

• The RSU grant and vesting schedule are consistent with typical long-term incentive plans observed in publicly traded companies, often designed to retain key executives and align their interests with shareholder returns over several years.
• The use of a Rule 10b5-1 plan for open market sales is a common practice among executives to sell shares in a pre-arranged, compliant manner, mitigating concerns about insider trading by establishing a trading plan in advance.

Stakeholder Impact

• Shareholders: The RSU grant aligns executive interests with long-term company performance. The share sales are minor relative to total outstanding shares and are not expected to have a material impact on the stock's float or price.
• Employees: The RSU grant is part of executive compensation, which can influence overall compensation strategies within the company.

Next Steps

• The remaining two-thirds of the awarded RSUs are expected to vest on the second and third anniversaries of the grant date (February 25, 2028, and February 25, 2029), subject to continued service.

Key Dates

Recommendation

This Form 4 details routine insider transactions related to executive compensation and tax obligations, including an RSU grant and subsequent share sales under a pre-arranged 10b5-1 plan. It does not provide new fundamental information to alter an investment thesis, thus a 'hold' recommendation is maintained.

Keywords

Bausch Health, BHC, Form 4, Insider Transaction, Restricted Share Units, RSU, Executive Compensation, Stock Sale, 10b5-1 Plan